Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human tumors. There are mainly point mutations that lead to single amino acid substitutions. The mutated proteins have a longer half-life than wild-type p53 and accumulate in the nucleus of tumor cells. Anti-p53 antibodies have been found in sera of patients with several types of cancers including breast cancer. This report describes a T cell immune response in three patients with breast tumors who had mutated p53 gene and accumulated p53 protein. All showed a humoral response to p53 protein and the T cells of these patients recognized the wild-type p53 protein and proliferated in response to it. The data reported here are relevant to the immune processes leading to autoimmunity and have a bearing on anti-p53 vaccine development in tumor immunology.
Tilkin
A F
AF
Unité INSERM 152, Institut Cochin de Génétique Moléculaire, Paris, France.
Lubin
R
R
Soussi
T
T
Lazar
V
V
Janin
N
N
Mathieu
M C
MC
Lefrère
I
I
Carlu
C
C
Roy
M
M
Kayibanda
M
M
D000906:Antibodies / Q000097:blood; D001483:Base Sequence; D001943:Breast Neoplasms / Q000276:immunology*; D002455:Cell Division; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008969:Molecular Sequence Data; D009154:Mutation; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000276:immunology*
D000906:Antibodies; D016159:Tumor Suppressor Protein p53